If I could only buy one ASX 200 share today, it would be CSL Ltd (ASX: CSL).
Let me explain why.
I think headwinds are easing
The ASX 200 biotech company has faced huge headwinds over the past 18 months.
From uninspiring financial results, to a revenue and growth profit guidance downgrade, a surprise restructure announcement, and even a shock CEO exit, several events have spooked investors and sent the company’s share price south.
At the time of writing, the CSL share price is up 0.8% to $141.93 a piece. Today’s uptick represents a 5.5% rebound from an eight-year low of $134.64 just two weeks ago.
There is a long way to go until CSL shares recover the 43% losses shed over the past 12 months, but the latest uptick is a great sign that the share price has finally bottomed out and is starting to rebound.
There is huge demand for its products
Another reason I’d buy CSL shares today is because of huge global demand for its productions.
CSL develops and delivers biotherapies and vaccines but at the core of its business are its plasma-derived medicines. These include immunoglobulins, albumin, and clotting factors.
At the time of writing, the company’s blood plasma division dominates the global market for rare blood disorders and immunoglobulin products.
Demand for these plasma therapies is rocketing right now. There is recurring demand, limited competition and low supply which means CSL is well placed to absorb a significant portion of the market.
For context, reports recently stated that the blood plasma derivatives market was valued at $52.16 billion in 2025. By 2033 it is expected to explode to $104.30 billion.
The ASX 200 company is growing
Despite the latest headwinds, CSL has still managed to maintain business growth. The company has even experienced periods of doubleâdigit profit growth, and its forecasts underpin a recovery over the long term.
Sequoia Wealth Management’s Peter Day, who has a buy recommendation on CSL shares, recently pointed out that the company has posted a significant increase in revenue during the past three years and delivered earnings growth that is compounding at double-digit rates.
There’s a great potential upside ahead
I’m confident that we’ll see great things out of the CSL share price this year.
Analysts are bullish too.
TradingView data shows that 12 out of 18 analysts have a buy or strong buy rating on the ASX 200 stock. They tip an upside of up to 95% to $275.56 over the next 12 months, at the time of writing.
It’s seems like CSL shares are a no-brainer to me.
The post If I could buy only 1 ASX 200 share right now, it would be… appeared first on The Motley Fool Australia.
Should you invest $1,000 in CSL right now?
Before you buy CSL shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and CSL wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 20 Feb 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- CSL shares slide again in March â but is a comeback brewing?
- How are these 5 ASX share giants really tracking in 2026?
- Is it time to get greedy with CSL shares?
- Why I’d buy dirt-cheap ASX shares now and aim to hold them for a decade
- Is it too late to start investing in ASX shares in your 40s?
Motley Fool contributor Samantha Menzies has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.